ArriVent BioPharma Inc. C... (AVBP)
NASDAQ: AVBP
· Real-Time Price · USD
19.54
0.92 (4.94%)
At close: Aug 15, 2025, 3:59 PM
19.58
0.20%
After-hours: Aug 15, 2025, 05:41 PM EDT
ArriVent BioPharma Common Stock Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -33.62M | -66.77M | -23.7M | -24.23M | -25.7M | -20.67M | -23.12M | -16.72M | -22.58M | -12.17M | -10.44M | -11.77M | -7.35M | -7.35M |
Interest Income | 2.22M | 2.38M | 3.07M | 3.67M | 3.82M | 3.26M | 1.93M | 2.31M | 1.02M | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -31.4M | -64.39M | -20.63M | -20.56M | -21.87M | -17.42M | -21.19M | -14.4M | -21.57M | -12.17M | -10.44M | -11.77M | -7.35M | -7.35M |
Net Income | -31.4M | -64.39M | -20.63M | -20.56M | -21.87M | -17.42M | -21.19M | -14.4M | -21.57M | -12.17M | -10.44M | -11.77M | -7.35M | -7.35M |
Selling & General & Admin | 5.9M | 5.48M | 3.54M | 4.14M | 3.92M | 3.7M | 3.11M | 2.44M | 2.23M | 1.94M | 1.79M | 1.68M | 1.5M | 1.5M |
Research & Development | 27.72M | 61.29M | 20.16M | 20.09M | 21.78M | 16.98M | 20.01M | 14.28M | 20.36M | 10.24M | 8.65M | 10.09M | 5.85M | 5.85M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 33.62M | 66.77M | 23.7M | 24.23M | 25.7M | 20.67M | 23.12M | 16.72M | 22.58M | 12.17M | 10.44M | 11.77M | 7.35M | 7.35M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 33.62M | 66.77M | 23.7M | 24.23M | 25.7M | 20.67M | 23.12M | 16.72M | 22.58M | 12.17M | 10.44M | 11.77M | 7.35M | 7.35M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 35.01M | 33.9M | 33.58M | 33.58M | 33.51M | 33.49M | 33.49M | 33.49M | 33.49M | 33.49M | 33.49M | 33.49M | 1.28M | 1.28M |
Shares Outstanding (Diluted) | 35.01M | 33.9M | 33.58M | 33.58M | 33.51M | 33.49M | 33.49M | 33.49M | 33.49M | 33.49M | 33.49M | 33.49M | 1.28M | 1.28M |
EPS (Basic) | -0.9 | -1.9 | -0.61 | -0.61 | -0.65 | -0.52 | -0.63 | -0.43 | -0.64 | -0.36 | -0.31 | -0.35 | -5.76 | -5.76 |
EPS (Diluted) | -0.9 | -1.9 | -0.61 | -0.61 | -0.65 | -0.52 | -0.63 | -0.43 | -0.64 | -0.36 | -0.31 | -0.35 | -5.76 | -5.76 |
EBITDA | -31.4M | -66.77M | -23.7M | -24.23M | -25.7M | -20.67M | -23.12M | -16.72M | -22.58M | -12.17M | -10.44M | -11.77M | n/a | n/a |
EBIT | -31.4M | -66.77M | -23.7M | -24.23M | -25.7M | -20.67M | -23.12M | -16.72M | -22.58M | -12.17M | -10.44M | -11.77M | -7.35M | -7.35M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 12.17M | 10.44M | 11.77M | 7.35M | 7.35M |